Inventor · disambiguated record
Andrew Hughes
Also filed as: HUGHES ANDREW · HUGHES ANDREW M · HUGHES ANDREW MARK
1 granted patent·5 pending applications·0 citations·filing 2003–2010
14Inventor score
Top patents by PatentIndex Score
6 records- 0154US2010035896A1Combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agentASTRAZENECA AB·Filed 2009·Application pending·0 cites
- 0254US2008076780A1Combination of N-(3-Methoxy-5-Methylpyrazin-2-Yl)-2-(4-[1,3,4-Oxadiazol-2-Yl]Phenyl)Pyridine-3-Sulphonamide and an Anti-Mitotic Cytotoxic AgentASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 0343US7820679B2N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agentASTRAZENECA AB·Filed 2003·Granted Oct 26, 2010·0 cites·9 claims
- 0434US2011003831A1N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agentASTRAZENECA AB·Filed 2010·Application pending·0 cites
- 0533US2006009512A15-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonistASTRAZENECA AB·Filed 2003·Application pending·0 cites
- 0630US2006122180A1Therapeutic treatmentBOYLE FRANCIS T·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →